BMP signaling in vascular development and disease

Cytokine and Growth Factor Reviews

Volumn 21, Issue 4, 2010, Pages 287-298

  Lowery, Jonathan W ^a   de Caestecker, M P ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BMP; Bone morphogenetic protein; Development; Disease; Signaling; Vasculature

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 9; BONE MORPHOGENETIC PROTEIN RECEPTOR; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; ENDOGLIN; SMAD PROTEIN; SMAD1 PROTEIN; SMAD4 PROTEIN; SMAD5 PROTEIN; SMAD6 PROTEIN; SMAD8 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1;

ANGIOGENESIS; ARTERIOVENOUS MALFORMATION; BLOOD VESSEL CALCIFICATION; CONGENITAL BLOOD VESSEL MALFORMATION; EMBRYO DEVELOPMENT; GENETIC DISORDER; HOMEOSTASIS; HUMAN; LIGAND BINDING; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PULMONARY HYPERTENSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

ADULT; ANIMALS; BLOOD VESSELS; BONE MORPHOGENETIC PROTEIN RECEPTORS; BONE MORPHOGENETIC PROTEINS; EMBRYONIC DEVELOPMENT; HOMEOSTASIS; HUMANS; HYPERTENSION, PULMONARY; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION; SMAD PROTEINS; VASCULAR DISEASES;

EID: 77956404810     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2010.06.001     Document Type: Review

References (199)

1. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., et al. Novel regulators of bone formation: molecular clones and activities. Science 1988, 242:1528-1534.
2. Kishigami S., Mishina Y. BMP signaling and early embryonic patterning. Cytokine Growth Factor Rev 2005, 16:265-278.
3. Zhao G.Q. Consequences of knocking out BMP signaling in the mouse. Genesis 2003, 35:43-56.
4. Andersson O., Bertolino P., Ibanez C.F. Distinct and cooperative roles of mammalian Vg1 homologs GDF1 and GDF3 during early embryonic development. Dev Biol 2007, 311:500-511.
5. Andersson O., Reissmann E., Ibanez C.F. Growth differentiation factor 11 signals through the transforming growth factor-beta receptor ALK5 to regionalize the anterior-posterior axis. EMBO Rep 2006, 7:831-837.
6. Rebbapragada A., Benchabane H., Wrana J.L., Celeste A.J., Attisano L. Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis. Mol Cell Biol 2003, 23:7230-7242.
7. Gamer L.W., Nove J., Levin M., Rosen V. BMP-3 is a novel inhibitor of both activin and BMP-4 signaling in Xenopus embryos. Dev Biol 2005, 285:156-168.
8. Wiater E., Vale W. Inhibin is an antagonist of bone morphogenetic protein signaling. J Biol Chem 2003, 278:7934-7941.
9. Pregizer S., Mortlock D.P. Control of BMP gene expression by long-range regulatory elements. Cytokine Growth Factor Rev 2009, 20:509-515.
10. Cui Y., Jean F., Thomas G., Christian J.L. BMP-4 is proteolytically activated by furin and/or PC6 during vertebrate embryonic development. EMBO J 1998, 17:4735-4743.
11. Constam D.B., Robertson E.J. Regulation of bone morphogenetic protein activity by pro domains and proprotein convertases. J Cell Biol 1999, 144:139-149.
12. Goldman D.C., Hackenmiller R., Nakayama T., Sopory S., Wong C., Kulessa H., et al. Mutation of an upstream cleavage site in the BMP4 prodomain leads to tissue-specific loss of activity. Development 2006, 133:1933-1942.
13. Gregory K.E., Ono R.N., Charbonneau N.L., Kuo C.L., Keene D.R., Bachinger H.P., et al. The prodomain of BMP-7 targets the BMP-7 complex to the extracellular matrix. J Biol Chem 2005, 280:27970-27980.
14. Brown M.A., Zhao Q., Baker K.A., Naik C., Chen C., Pukac L., et al. Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem 2005, 280:25111-25118.
15. Umulis D., O'Connor M.B., Blair S.S. The extracellular regulation of bone morphogenetic protein signaling. Development 2009, 136:3715-3728.
16. Seemann P., Brehm A., Konig J., Reissner C., Stricker S., Kuss P., et al. Mutations in GDF5 reveal a key residue mediating BMP inhibition by NOGGIN. PLoS Genet 2009, 5(11):e1000747.
17. Zimmerman L.B., De Jesus-Escobar J.M., Harland R.M. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 1996, 86:599-606.
18. Piccolo S., Sasai Y., Lu B., De Robertis E.M. Dorsoventral patterning in Xenopus: inhibition of ventral signals by direct binding of chordin to BMP-4. Cell 1996, 86:589-598.
19. Larrain J., Oelgeschlager M., Ketpura N.I., Reversade B., Zakin L., De Robertis E.M. Proteolytic cleavage of chordin as a switch for the dual activities of twisted gastrulation in BMP signaling. Development 2001, 128:4439-4447.
20. Miyazono K., Kamiya Y., Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem 2010, 147:35-51.
21. Moustakas A., Heldin C.H. The regulation of TGFbeta signal transduction. Development 2009, 136:3699-3714.
22. Chan M.C., Nguyen P.H., Davis B.N., Ohoka N., Hayashi H., Du K., et al. A novel regulatory mechanism of the bone morphogenetic protein (BMP) signaling pathway involving the carboxyl-terminal tail domain of BMP type II receptor. Mol Cell Biol 2007, 27:5776-5789.
23. Schwappacher R., Weiske J., Heining E., Ezerski V., Marom B., Henis Y.I., et al. Novel crosstalk to BMP signalling: cGMP-dependent kinase I modulates BMP receptor and Smad activity. EMBO J 2009, 28:1537-1550.
24. Lee-Hoeflich S.T., Causing C.G., Podkowa M., Zhao X., Wrana J.L., Attisano L. Activation of LIMK1 by binding to the BMP receptor, BMPRII, regulates BMP-dependent dendritogenesis. EMBO J 2004, 23:4792-4801.
25. Nickel J., Sebald W., Groppe J.C., Mueller T.D. Intricacies of BMP receptor assembly. Cytokine Growth Factor Rev 2009, 20:367-377.
26. Sampath T.K., Coughlin J.E., Whetstone R.M., Banach D., Corbett C., Ridge R.J., et al. Bovine osteogenic protein is composed of dimers of OP-1 and BMP-2A, two members of the transforming growth factor-beta superfamily. J Biol Chem 1990, 265:13198-13205.
27. Hazama M., Aono A., Ueno N., Fujisawa Y. Efficient expression of a heterodimer of bone morphogenetic protein subunits using a baculovirus expression system. Biochem Biophys Res Commun 1995, 209:859-866.
28. Little S.C., Mullins M.C. Bone morphogenetic protein heterodimers assemble heteromeric type I receptor complexes to pattern the dorsoventral axis. Nat Cell Biol 2009, 11:637-643.
29. Mazerbourg S., Klein C., Roh J., Kaivo-Oja N., Mottershead D.G., Korchynskyi O., et al. Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5. Mol Endocrinol 2004, 18:653-665.
30. Vitt U.A., Mazerbourg S., Klein C., Hsueh A.J. Bone morphogenetic protein receptor type II is a receptor for growth differentiation factor-9. Biol Reprod 2002, 67:473-480.
31. Daly A.C., Randall R.A., Hill C.S. Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol Cell Biol 2008, 28:6889-6902.
32. Goumans M.J., Valdimarsdottir G., Itoh S., Lebrin F., Larsson J., Mummery C., et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 2003, 12:817-828.
33. Goumans M.J., Valdimarsdottir G., Itoh S., Rosendahl A., Sideras P., ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002, 21:1743-1753.
34. Piek E., Afrakhte M., Sampath K., van Zoelen E.J., Heldin C.H., ten Dijke P. Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells. J Cell Physiol 1999, 180:141-149.
35. Kirkbride K.C., Ray B.N., Blobe G.C. Cell-surface co-receptors: emerging roles in signaling and human disease. Trends Biochem Sci 2005, 30:611-621.
36. Lopez-Casillas F., Payne H.M., Andres J.L., Massague J. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol 1994, 124:557-568.
37. Venkatesha S., Toporsian M., Lam C., Hanai J., Mammoto T., Kim Y.M., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006, 12:642-649.
38. Kirkbride K.C., Townsend T.A., Bruinsma M.W., Barnett J.V., Blobe G.C. Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. J Biol Chem 2008, 283:7628-7637.
39. Lewis K.A., Gray P.C., Blount A.L., MacConell L.A., Wiater E., Bilezikjian L.M., et al. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 2000, 404:411-414.
40. Kirkbride K.C., Townsend T.A., Bruinsma M.W., Barnett J.V., Blobe G.C. Bone morphogenetic proteins signal through the transforming growth factor-β type III receptor. J Biol Chem 2008, 283:7628-7637.
41. Lee N.Y., Kirkbride K.C., Sheu R.D., Blobe G.C. The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors. Mol Biol Cell 2009, 20:4362-4370.
42. Barbara N.P., Wrana J.L., Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-β superfamily. J Biol Chem 1999, 274:584-594.
43. Scharpfenecker M., van Dinther M., Liu Z., van Bezooijen R.L., Zhao Q., Pukac L., et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 2007, 120:964-972.
44. David L., Mallet C., Mazerbourg S., Feige J.J., Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 2007, 109:1953-1961.
45. Scherner O., Meurer S.K., Tihaa L., Gressner A.M., Weiskirchen R. Endoglin differentially modulates antagonistic transforming growth factor-beta1 and BMP-7 signaling. J Biol Chem 2007, 282:13934-13943.
46. Barbara N.P., Wrana J.L., Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999, 274:584-594.
47. Ray B.N., Lee N.Y., How T., Blobe G.C. ALK5 phosphorylation of the endoglin cytoplasmic domain regulates Smad1/5/8 signaling and endothelial cell migration. Carcinogenesis 2009, 31(3):435-441.
48. Ross S., Hill C.S. How the Smads regulate transcription. Int J Biochem Cell Biol 2008, 40:383-408.
49. Shi Y., Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
50. Wrighton K.H., Lin X., Yu P.B., Feng X.H. Transforming growth factor {beta} can stimulate smad1 phosphorylation independently of bone morphogenic protein receptors. J Biol Chem 2009, 284:9755-9763.
51. Liu I.M., Schilling S.H., Knouse K.A., Choy L., Derynck R., Wang X.F. TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. EMBO J 2009, 28:88-98.
52. Ishibashi O., Ikegame M., Takizawa F., Yoshizawa T., Moksed M.A., Iizawa F., et al. Endoglin is involved in BMP-2-induced osteogenic differentiation of periodontal ligament cells through a pathway independent of Smad-1/5/8 phosphorylation. J Cell Physiol 2010, 222:465-473.
53. Upton P.D., Davies R.J., Trembath R.C., Morrell N.W. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J Biol Chem 2009, 284:15794-15804.
54. Lonn P., Moren A., Raja E., Dahl M., Moustakas A. Regulating the stability of TGFbeta receptors and Smads. Cell Res 2009, 19:21-35.
55. Wrighton K.H., Lin X., Feng X.H. Phospho-control of TGF-beta superfamily signaling. Cell Res 2009, 19:8-20.
56. Funaba M., Zimmerman C.M., Mathews L.S. Modulation of Smad2-mediated signaling by extracellular signal-regulated kinase. J Biol Chem 2002, 277:41361-41368.
57. de Caestecker M.P., Parks W.T., Frank C.J., Castagnino P., Bottaro D.P., Roberts A.B., et al. Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes Dev 1998, 12:1587-1592.
58. Liu Y., Ren W., Warburton R., Toksoz D., Fanburg B.L. Serotonin induces Rho/ROCK-dependent activation of Smads 1/5/8 in pulmonary artery smooth muscle cells. FASEB J 2009, 23:2299-2306.
59. Hussein S.M., Duff E.K., Sirard C. Smad4 and beta-catenin co-activators functionally interact with lymphoid-enhancing factor to regulate graded expression of Msx2. J Biol Chem 2003, 278:48805-48814.
60. Itoh F., Itoh S., Goumans M.J., Valdimarsdottir G., Iso T., Dotto G.P., et al. Synergy and antagonism between Notch and BMP receptor signaling pathways in endothelial cells. EMBO J 2004, 23:541-551.
61. Davis B.N., Hilyard A.C., Lagna G., Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 2008, 454:56-61.
62. Baek D., Villen J., Shin C., Camargo F.D., Gygi S.P., Bartel D.P. The impact of microRNAs on protein output. Nature 2008, 455:64-71.
63. Selbach M., Schwanhausser B., Thierfelder N., Fang Z., Khanin R., Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455:58-63.
64. Chan M.C., Hilyard A.C., Wu C., Davis B.N., Hill N.S., Lal A., et al. Molecular basis for antagonism between PDGF and the TGFbeta family of signalling pathways by control of miR-24 expression. EMBO J 2010, 29(3):559-573.
65. Zhang Y.E. Non-Smad pathways in TGF-beta signaling. Cell Res 2009, 19:128-139.
66. Gilboa L., Nohe A., Geissendorfer T., Sebald W., Henis Y.I., Knaus P. Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors. Mol Biol Cell 2000, 11:1023-1035.
67. Hassel S., Schmitt S., Hartung A., Roth M., Nohe A., Petersen N., et al. Initiation of Smad-dependent and Smad-independent signaling via distinct BMP-receptor complexes. J Bone Joint Surg Am 2003, 85A(Suppl. 3):44-51.
68. Nohe A., Hassel S., Ehrlich M., Neubauer F., Sebald W., Henis Y.I., et al. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 2002, 277:5330-5338.
69. Yamaguchi K., Nagai S., Ninomiya-Tsuji J., Nishita M., Tamai K., Irie K., et al. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO J 1999, 18:179-187.
70. Shibuya H., Yamaguchi K., Shirakabe K., Tonegawa A., Gotoh Y., Ueno N., et al. TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 1996, 272:1179-1182.
71. Yamaguchi K., Shirakabe K., Shibuya H., Irie K., Oishi I., Ueno N., et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995, 270:2008-2011.
72. Shim J.H., Greenblatt M.B., Xie M., Schneider M.D., Zou W., Zhai B., et al. TAK1 is an essential regulator of BMP signalling in cartilage. EMBO J 2009, 28:2028-2041.
73. Corriere M.A., Rogers C.M., Eliason J.L., Faulk J., Kume T., Hogan B.L., et al. Endothelial Bmp4 is induced during arterial remodeling: effects on smooth muscle cell migration and proliferation. J Surg Res 2008, 145:142-149.
74. Bostrom K., Watson K.E., Horn S., Wortham C., Herman I.M., Demer L.L. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 1993, 91:1800-1809.
75. Sorescu G.P., Sykes M., Weiss D., Platt M.O., Saha A., Hwang J., et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress stimulates an inflammatory response. J Biol Chem 2003, 278:31128-31135.
76. Csiszar A., Smith K.E., Koller A., Kaley G., Edwards J.G., Ungvari Z. Regulation of bone morphogenetic protein-2 expression in endothelial cells: role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2, and high intravascular pressure. Circulation 2005, 111:2364-2372.
77. Nakaoka T., Gonda K., Ogita T., Otawara-Hamamoto Y., Okabe F., Kira Y., et al. Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. J Clin Invest 1997, 100:2824-2832.
78. Miriyala S., Gongora Nieto M.C., Mingone C., Smith D., Dikalov S., Harrison D.G., et al. Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation 2006, 113:2818-2825.
79. Csiszar A., Ahmad M., Smith K.E., Labinskyy N., Gao Q., Kaley G., et al. Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype. Am J Pathol 2006, 168:629-638.
80. Sorescu G.P., Song H., Tressel S.L., Hwang J., Dikalov S., Smith D.A., et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res 2004, 95:773-779.
81. Csiszar A., Labinskyy N., Jo H., Ballabh P., Ungvari Z. Differential proinflammatory and prooxidant effects of bone morphogenetic protein-4 in coronary and pulmonary arterial endothelial cells. Am J Physiol Heart Circ Physiol 2008, 295:H569-H577.
82. Frank D.B., Abtahi A., Yamaguchi D.J., Manning S., Shyr Y., Pozzi A., et al. Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. Circ Res 2005, 97:496-504.
83. Meyrick B., Reid L. Pulmonary hypertension. Anatomic and physiologic correlates. Clin Chest Med 1983, 4:199-217.
84. Anderson L., Lowery J.W., Frank D.B., Novitskaya T., Jones M., Mortlock D.P., et al. Bmp2 and Bmp4 exert opposing effects in hypoxic pulmonary hypertension. Am J Physiol Regul Integr Comp Physiol 2010, 298:R833-R842.
85. Lagna G., Nguyen P.H., Ni W., Hata A. BMP-dependent activation of caspase-9 and caspase-8 mediates apoptosis in pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2006, 291:L1059-L1067.
86. Takeda M., Otsuka F., Nakamura K., Inagaki K., Suzuki J., Miura D., et al. Characterization of the bone morphogenetic protein (BMP) system in human pulmonary arterial smooth muscle cells isolated from a sporadic case of primary pulmonary hypertension: roles of BMP type IB receptor (activin receptor-like kinase-6) in the mitotic action. Endocrinology 2004, 145:4344-4354.
87. Yang X., Long L., Southwood M., Rudarakanchana N., Upton P.D., Jeffery T.K., et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res 2005, 96:1053-1063.
88. Frank D.B., Lowery J., Anderson L., Brink M., Reese J., de Caestecker M. Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature. Am J Physiol Lung Cell Mol Physiol 2008, 294:L98-L109.
89. Herrera B., Inman G.J. A rapid and sensitive bioassay for the simultaneous measurement of multiple bone morphogenetic proteins. Identification and quantification of BMP4, BMP6 and BMP9 in bovine and human serum. BMC Cell Biol 2009, 10:20.
90. David L., Mallet C., Keramidas M., Lamande N., Gasc J.M., Dupuis-Girod S., et al. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ Res 2008, 102:914-922.
91. Heinke J., Wehofsits L., Zhou Q., Zoeller C., Baar K.M., Helbing T., et al. BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis. Circ Res 2008, 103:804-812.
92. Ren R., Charles P.C., Zhang C., Wu Y., Wang H., Patterson C. Gene expression profiles identify a role for cyclooxygenase 2-dependent prostanoid generation in BMP6-induced angiogenic responses. Blood 2007, 109:2847-2853.
93. Maciel T.T., Melo R.S., Schor N., Campos A.H. Gremlin promotes vascular smooth muscle cell proliferation and migration. J Mol Cell Cardiol 2008, 44:370-379.
94. Jara A., Chacon C., Burgos M.E., Droguett A., Valdivieso A., Ortiz M., et al. Expression of gremlin, a bone morphogenetic protein antagonist,is associated with vascular calcification in uraemia. Nephrol Dial Transplant 2009, 24:1121-1129.
95. Costello C.M., Howell K., Cahill E., McBryan J., Konigshoff M., Eickelberg O., et al. Lung-selective gene responses to alveolar hypoxia: potential role for the bone morphogenetic antagonist gremlin in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2008, 295:L272-L284.
96. Chang K., Weiss D., Suo J., Vega J.D., Giddens D., Taylor W.R., et al. Bone morphogenic protein antagonists are coexpressed with bone morphogenic protein 4 in endothelial cells exposed to unstable flow in vitro in mouse aortas and in human coronary arteries: role of bone morphogenic protein antagonists in inflammation and atherosclerosis. Circulation 2007, 116:1258-1266.
97. Moser M., Yu Q., Bode C., Xiong J.W., Patterson C. BMPER is a conserved regulator of hematopoietic and vascular development in zebrafish. J Mol Cell Cardiol 2007, 43:243-253.
98. Zebboudj A.F., Imura M., Boström K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 2002, 277:4388-4394.
99. Yao Y., Zebboudj A.F., Shao E., Perez M., Bostrom K. Regulation of bone morphogenetic protein-4 by matrix GLA protein in vascular endothelial cells involves activin-like kinase receptor 1. J Biol Chem 2006, 281:33921-33930.
100. Luo G., Ducy P., McKee M.D., Pinero G.J., Loyer E., Behringer R.R., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997, 386:78-81.
101. Hur D.J., Raymond G.V., Kahler S.G., Riegert-Johnson D.L., Cohen B.A., Boyadjiev S.A. A novel MGP mutation in a consanguineous family: review of the clinical and molecular characteristics of Keutel syndrome. Am J Med Genet A 2005, 135:36-40.
102. Yao Y., Nowak S., Yochelis A., Garfinkel A., Bostrom K.I. Matrix GLA protein, an inhibitory morphogen in pulmonary vascular development. J Biol Chem 2007, 282:30131-30142.
103. Machado R.D., Aldred M.A., James V., Harrison R.E., Patel B., Schwalbe E.C., et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006, 27:121-132.
104. Machado R.D., Eickelberg O., Elliott C.G., Geraci M.W., Hanaoka M., Loyd J.E., et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54:S32-S42.
105. Simonneau G., Galie N., Rubin L.J., Langleben D., Seeger W., Domenighetti G., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43:5S-12S.
106. Du L., Sullivan C.C., Chu D., Cho A.J., Kido M., Wolf P.L., et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med 2003, 348:500-509.
107. Atkinson C., Stewart S., Upton P.D., Machado R., Thomson J.R., Trembath R.C., et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002, 105:1672-1678.
108. Liu D., Wang J., Kinzel B., Mueller M., Mao X., Valdez R., et al. Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrity. Blood 2007, 110:1502-1510.
109. Hong K.-H., Lee Y.J., Lee E., Park S.O., Han C., Beppu H., et al. Genetic ablation of the Bmpr2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation 2008, 118:722-730.
110. West J., Harral J., Lane K., Deng Y., Ickes B., Crona D., et al. Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions. Am J Physiol Lung Cell Mol Physiol 2008, 295:L744-L755.
111. Hassoun P.M., Mouthon L., Barbera J.A., Eddahibi S., Flores S.C., Grimminger F., et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009, 54:S10-S19.
112. Song Y., Coleman L., Shi J., Beppu H., Sato K., Walsh K., et al. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. Am J Physiol Heart Circ Physiol 2008, 295:H677-H690.
113. Song Y., Jones J.E., Beppu H., Keaney J.F., Loscalzo J., Zhang Y.Y. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 2005, 112:553-562.
114. Long L., MacLean M.R., Jeffery T.K., Morecroft I., Yang X., Rudarakanchana N., et al. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 2006, 98:818-827.
115. Beppu H., Ichinose F., Kawai N., Jones R.C., Yu P.B., Zapol W.M., et al. BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol Lung Cell Mol Physiol 2004, 287:L1241-L1247.
116. Voelkel N.F., Tuder R.M. Hypoxia-induced pulmonary vascular remodeling: a model for what human disease?. J Clin Invest 2000, 106:733-738.
117. Sabba C., Pasculli G., Lenato G.M., Suppressa P., Lastella P., Memeo M., et al. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost 2007, 5:1149-1157.
118. Oh S.P., Seki T., Goss K.A., Imamura T., Yi Y., Donahoe P.K., et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 2000, 97:2626-2631.
119. Urness L.D., Sorensen L.K., Li D.Y. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 2000, 26:328-331.
120. Arthur H.M., Ure J., Smith A.J.H., Renforth G., Wilson D.I., Torsney E., et al. Endoglin, an ancillary TGF[beta] receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 2000, 217:42-53.
121. Srinivasan S., Hanes M.A., Dickens T., Porteous M.E., Oh S.P., Hale L.P., et al. A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet 2003, 12:473-482.
122. Park S.O., Lee Y.J., Seki T., Hong K.-H., Fliess N., Jiang Z., et al. ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood 2008, 111:633-642.
123. Harrison R.E., Flanagan J.A., Sankelo M., Abdalla S.A., Rowell J., Machado R.D., et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003, 40:865-871.
124. Park C., Lavine K., Mishina Y., Deng C.X., Ornitz D.M., Choi K. Bone morphogenetic protein receptor 1A signaling is dispensable for hematopoietic development but essential for vessel and atrioventricular endocardial cushion formation. Development 2006, 133:3473-3484.
125. El-Bizri N., Wang L., Merklinger S.L., Guignabert C., Desai T., Urashima T., et al. Smooth muscle protein 22alpha-mediated patchy deletion of Bmpr1a impairs cardiac contractility but protects against pulmonary vascular remodeling. Circ Res 2008, 102:380-388.
126. McAllister K.A., Grogg K.M., Johnson D.W., Gallione C.J., Baldwin M.A., Jackson C.E., et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994, 8:345-351.
127. Bourdeau A., Faughnan M.E., Letarte M. Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med 2000, 10:279-285.
128. Toporsian M., Jerkic M., Zhou Y.Q., Kabir M.G., Yu L.X., McIntyre B.A., et al. Spontaneous adult-onset pulmonary arterial hypertension attributable to increased endothelial oxidative stress in a murine model of hereditary hemorrhagic telangiectasia. Arterioscler Thromb Vasc Biol 2010, 30:509-517.
129. Belik J., Jerkic M., McIntyre B.A.S., Pan J., Leen J., Yu L.X., et al. Age-dependent endothelial nitric oxide synthase uncoupling in pulmonary arteries of endoglin heterozygous mice. Am J Physiol Lung Cell Mol Physiol 2009, 297:L1170-L1178.
130. Wang A., Rana S., Karumanchi S.A. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 2009, 24:147-158.
131. Bellon T., Corbi A., Lastres P., Cales C., Cebrian M., Vera S., et al. Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 1993, 23:2340-2345.
132. Perez-Gomez E., Eleno N., Lopez-Novoa J.M., Ramirez J.R., Velasco B., Letarte M., et al. Characterization of murine S-endoglin isoform and its effects on tumor development. Oncogene 2005, 24:4450-4461.
133. Blanco F.J., Grande M.T., Langa C., Oujo B., Velasco S., Rodriguez-Barbero A., et al. S-endoglin expression is induced in senescent endothelial cells and contributes to vascular pathology. Circ Res 2008, 103:1383-1392.
134. ten Dijke P., Goumans M.J., Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008, 11:79-89.
135. Arnold S.J., Maretto S., Islam A., Bikoff E.K., Robertson E.J. Dose-dependent Smad1, Smad5 and Smad8 signaling in the early mouse embryo. Dev Biol 2006, 296:104-118.
136. Chang H., Huylebroeck D., Verschueren K., Guo Q., Matzuk M.M., Zwijsen A. Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects. Development 1999, 126:1631-1642.
137. Yang X., Castilla L.H., Xu X., Li C., Gotay J., Weinstein M., et al. Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5. Development 1999, 126:1571-1580.
138. Umans L., Cox L., Tjwa M., Bito V., Vermeire L., Laperre K., et al. Inactivation of Smad5 in endothelial cells and smooth muscle cells demonstrates that Smad5 is required for cardiac homeostasis. Am J Pathol 2007, 170:1460-1472.
139. Lechleider R.J., Ryan J.L., Garrett L., Eng C., Deng C., Wynshaw-Boris A., et al. Targeted mutagenesis of Smad1 reveals an essential role in chorioallantoic fusion. Dev Biol 2001, 240:157-167.
140. Huang Z., Wang D., Ihida-Stansbury K., Jones P.L., Martin J.F. Defective pulmonary vascular remodeling in Smad8 mutant mice. Hum Mol Genet 2009, 18:2791-2801.
141. Shintani M., Yagi H., Nakayama T., Saji T., Matsuoka R. A new nonsense mutation of SMAD8 associated with pulmonary arterial hypertension. J Med Genet 2009, 46:331-337.
142. Howe J.R., Sayed M.G., Ahmed A.F., Ringold J., Larsen-Haidle J., Merg A., et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J Med Genet 2004, 41:484-491.
143. Sirard C., de la Pompa J.L., Elia A., Itie A., Mirtsos C., Cheung A., et al. The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev 1998, 12:107-119.
144. Yang X., Li C., Xu X., Deng C. The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc Natl Acad Sci USA 1998, 95:3667-3672.
145. Li D.Y., Sorensen L.K., Brooke B.S., Urness L.D., Davis E.C., Taylor D.G., et al. Defective angiogenesis in mice lacking endoglin. Science 1999, 284:1534-1537.
146. Lan Y., Liu B., Yao H., Li F., Weng T., Yang G., et al. Essential role of endothelial Smad4 in vascular remodeling and integrity. Mol Cell Biol 2007, 27:7683-7692.
147. Galvin K.M., Donovan M.J., Lynch C.A., Meyer R.I., Paul R.J., Lorenz J.N., et al. A role for smad6 in development and homeostasis of the cardiovascular system. Nat Genet 2000, 24:171-174.
148. Jadrich J.L., O'Connor M.B., Coucouvanis E. The TGF beta activated kinase TAK1 regulates vascular development in vivo. Development 2006, 133:1529-1541.
149. Hong C.C., Yu P.B. Applications of small molecule BMP inhibitors in physiology and disease. Cytokine Growth Factor Rev 2009, 20:409-418.
150. Shao E.S., Lin L., Yao Y., Bostrom K.I. Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood 2009, 114:2197-2206.
151. David L., Mallet C., Mazerbourg S., Feige J.-J., Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 2007, 109:1953-1961.
152. Mitchell D., Pobre E.G., Mulivor A.W., Grinberg A.V., Castonguay R., Monnell T.E., et al. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 2010, 9:379-388.
153. Ebisawa T., Tada K., Kitajima I., Tojo K., Sampath T., Kawabata M., et al. Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J Cell Sci 1999, 112:3519-3527.
154. ten Dijke P., Yamashita H., Sampath T.K., Reddi A.H., Estevez M., Riddle D.L., et al. Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem 1994, 269:16985-16988.
155. Maci{dotless}óas-Silva M., Hoodless P.A., Tang S.J., Buchwald M., Wrana J.L. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. J Biol Chem 1998, 273:25628-25636.
156. Yamashita H., ten Dijke P., Huylebroeck D., Sampath T.K., Andries M., Smith J.C., et al. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J Cell Biol 1995, 130:217-226.
157. Keller S., Nickel J., Zhang J.L., Sebald W., Mueller T.D. Molecular recognition of BMP-2 and BMP receptor IA. Nat Struct Mol Biol 2004, 11:481-488.
158. Nickel J., Dreyer M.K., Kirsch T., Sebald W. The crystal structure of the BMP-2:BMPR-IA complex and the generation of BMP-2 antagonists. J Bone Joint Surg Am 2001, 83:S7-S14.
159. Koenig B.B., Cook J.S., Wolsing D.H., Ting J., Tiesman J.P., Correa P.E., et al. Characterization and cloning of a receptor for BMP-2 and BMP-4 from NIH 3T3 cells. Mol Cell Biol 1994, 14:5961-5974.
160. Kirsch T., Sebald W., Dreyer M.K. Crystal structure of the BMP-2-BRIA ectodomain complex. Nat Struct Biol 2000, 7:492-496.
161. Kirsch T., Nickel J., Sebald W. Isolation of recombinant BMP receptor IA ectodomain and its 2:1 complex with BMP-2. FEBS Lett 2000, 468:215-219.
162. Yamaji N., Celeste A.J., Thies R.S., Song J.J., Bernier S.M., Goltzman D., et al. A mammalian serine/threonine kinase receptor specifically binds BMP-2 and BMP-4. Biochem Biophys Res Commun 1994, 205:1944-1951.
163. Allendorph G.P., Vale W.W., Choe S. Structure of the ternary signaling complex of a TGF-beta superfamily member. Proc Natl Acad Sci USA 2006, 103:7643-7648.
164. Hatta T., Konishi H., Katoh E., Natsume T., Ueno N., Kobayashi Y., et al. Identification of the ligand-binding site of the BMP type IA receptor for BMP-4. Pept Sci 2000, 55:399-406.
165. Beck H., Drahushuk K., Jacoby D., Higgins D., Lein P. Bone morphogenetic protein-5 (BMP-5) promotes dendritic growth in cultured sympathetic neurons. BMC Neurosci 2001, 2:12.
166. Mazerbourg S., Hsueh A.J. Genomic analyses facilitate identification of receptors and signalling pathways for growth differentiation factor 9 and related orphan bone morphogenetic protein/growth differentiation factor ligands. Hum Reprod Update 2006, 12:373-383.
167. Erlacher L., McCartney J., Piek E., ten Dijke P., Yanagishita M., Oppermann H., et al. Cartilage-derived morphogenetic proteins and osteogenic protein-1 differentially regulate osteogenesis. J Bone Miner Res 1998, 13:383-392.
168. Nishitoh H., Ichijo H., Kimura M., Matsumoto T., Makishima F., Yamaguchi A., et al. Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5. J Biol Chem 1996, 271:21345-21352.
169. Moore R.K., Otsuka F., Shimasaki S. Molecular basis of bone morphogenetic protein-15 signaling in granulosa cells. J Biol Chem 2003, 278:304-310.
170. Kirsch T., Nickel J., Sebald W. BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J 2000, 19:3314-3324.
171. Liu F., Ventura F., Doody J., Massague J. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol Cell Biol 1995, 15:3479-3486.
172. Rosenzweig B.L., Imamura T., Okadome T., Cox G.N., Yamashita H., ten Dijke P., et al. Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci USA 1995, 92:7632-7636.
173. Xia Y., Yu P.B., Sidis Y., Beppu H., Bloch K.D., Schneyer A.L., et al. Repulsive guidance molecule RGMa alters utilization of bone morphogenetic protein (BMP) type II receptors by BMP2 and BMP4. J Biol Chem 2007, 282:18129-18140.
174. Greenwald J., Groppe J., Gray P., Wiater E., Kwiatkowski W., Vale W., et al. The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol Cell 2003, 11:605-617.
175. Babitt J.L., Zhang Y., Samad T.A., Xia Y., Tang J., Campagna J.A., et al. Repulsive guidance molecule (RGMa), a DRAGON homologue, is a bone morphogenetic protein co-receptor. J Biol Chem 2005, 280:29820-29827.
176. Halbrooks P.J., Ding R., Wozney J.M., Bain G. Role of RGM coreceptors in bone morphogenetic protein signaling. J Mol Signal 2007, 2:4.
177. Samad T.A., Rebbapragada A., Bell E., Zhang Y., Sidis Y., Jeong S.J., et al. DRAGON, a bone morphogenetic protein co-receptor. J Biol Chem 2005, 280:14122-14129.
178. Kuns-Hashimoto R., Kuninger D., Nili M., Rotwein P. Selective binding of RGMc/hemojuvelin, a key protein in systemic iron metabolism, to BMP-2 and neogenin. Am J Physiol Cell Physiol 2008, 294:C994-C1003.
179. Yang F., West A.P., Allendorph G.P., Choe S., Bjorkman P.J. Neogenin interacts with hemojuvelin through its two membrane-proximal fibronectin type III domains. Biochemistry 2008, 47:4237-4245.
180. Xia Y., Babitt J.L., Sidis Y., Chung R.T., Lin H.Y. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood 2008, 111:5195-5204.
181. Babitt J.L., Huang F.W., Wrighting D.M., Xia Y., Sidis Y., Samad T.A., et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006, 38:531-539.
182. Andriopoulos B., Corradini E., Xia Y., Faasse S.A., Chen S., Grgurevic L., et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009, 41:482-487.
183. Onichtchouk D., Chen Y.G., Dosch R., Gawantka V., Delius H., Massague J., et al. Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature 1999, 401:480-485.
184. Jin W., Yun C., Kim H.S., Kim S.J. TrkC binds to the bone morphogenetic protein type II receptor to suppress bone morphogenetic protein signaling. Cancer Res 2007, 67:9869-9877.
185. Sammar M., Sieber C., Knaus P. Biochemical and functional characterization of the Ror2/BRIb receptor complex. Biochem Biophys Res Commun 2009, 381:1-6.
186. Sammar M., Stricker S., Schwabe G.C., Sieber C., Hartung A., Hanke M., et al. Modulation of GDF5/BRI-b signalling through interaction with the tyrosine kinase receptor Ror2. Genes Cells 2004, 9:1227-1238.
187. Rigelsky C.M., Jennings C., Lehtonen R., Minai O.A., Eng C., Aldred M.A. BMPR2 mutation in a patient with pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia. Am J Med Genet A 2008, 146A:2551-2556.
188. Park S.O., Wankhede M., Lee Y.J., Choi E.J., Fliess N., Choe S.W., et al. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest 2009, 119:3487-3496.
189. Fujiwara M., Yagi H., Matsuoka R., Akimoto K., Furutani M., Imamura S., et al. Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. Circ J 2008, 72:127-133.
190. Johnson D.W., Berg J.N., Baldwin M.A., Gallione C.J., Marondel I., Yoon S.J., et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996, 13:189-195.
191. El-Bizri N., Guignabert C., Wang L., Cheng A., Stankunas K., Chang C.P., et al. SM22alpha-targeted deletion of bone morphogenetic protein receptor 1A in mice impairs cardiac and vascular development, and influences organogenesis. Development 2008, 135:2981-2991.
192. Bourdeau A., Cymerman U., Paquet M.E., Meschino W., McKinnon W.C., Guttmacher A.E., et al. Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1. Am J Pathol 2000, 156:911-923.
193. Mahmoud M., Allinson K.R., Zhai Z., Oakenfull R., Ghandi P., Adams R.H., et al. Pathogenesis of arteriovenous malformations in the absence of endoglin. Circ Res 2010, 106:1425-1433.
194. Lesca G., Burnichon N., Raux G., Tosi M., Pinson S., Marion M.J., et al. Distribution of ENG and ACVRL1 (ALK1) mutations in French HHT patients. Hum Mutat 2006, 27(6):598.
195. Gallione C., Aylsworth A.S., Beis J., Berk T., Bernhardt B., Clark R.D., et al. Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome. Am J Med Genet A 2010, 152A:333-339.
196. Gallione C.J., Richards J.A., Letteboer T.G., Rushlow D., Prigoda N.L., Leedom T.P., et al. SMAD4 mutations found in unselected HHT patients. J Med Genet 2006, 43:793-797.
197. Chang H., Brown C.W., Matzuk M.M. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 2002, 23:787-823.
198. Tamura K., Dudley J., Nei M., Kumar S. MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24:1596-1599.
199. Saitou N., Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987, 4:406-425.